The glucocorticoid receptor is a co-regulator of the orphan nuclear receptor Nurr1.
Carpentier R, Sacchetti P, Ségard P, Staels B, Lefebvre P
The glucocorticoid receptor physically interacts with Nurr1 to regulate its transcriptional activity, suggesting that stress hormones can indirectly control this protein. This interaction provides a potential mechanism for pharmacologically modulating Nurr1 levels using existing glucocorticoid drugs. However, the study relies on molecular biology techniques and does not involve human patients or animal models of NR4A2 syndrome.
- Glucocorticoid receptor binds directly to Nurr1 in brain regions like the substantia nigra.
- This interaction allows glucocorticoids to regulate Nurr1's transcriptional activity.
- Co-regulators SMRT and SRC2 modulate the combined effect of these two receptors.
- The study identifies a molecular pathway but lacks clinical or animal model data.
- No evidence is provided regarding human NR4A2 variants or patient outcomes.
Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons.
Bauer M, Szulc J, Meyer M, Jensen CH, Terki TA, Meixner A, Kinkl N, Gasser T, Aebischer P, Ueffing M
This study identifies Delta-like 1 (Dlk1) as a protein that supports the development of dopamine-producing neurons in the midbrain. Removing Dlk1 reduces the number of these neurons, while adding it increases their production during early growth stages.
- Dlk1 is expressed in mouse ventral midbrain progenitors and mature dopamine neurons.
- Adding soluble Dlk1 boosts the proliferation of dopamine progenitor cells.
- Silencing Dlk1 prevents the expression of key dopamine neuron markers.
- Dlk1 appears to have a permissive role in dopamine neuron differentiation.
Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons.
Hong S, Kang UJ, Isacson O, Kim KS
Human embryonic stem cells expand significantly in the lab while retaining the ability to become dopaminergic neurons and other neural types. These expanded precursors maintain their potential for over two years when frozen, providing a scalable source of human neural cells.
- Human neural precursors expand 380,000-fold in culture without losing differentiation potential.
- Cells generate neurons, astrocytes, and oligodendrocytes, including dopamine-producing neurons.
- Dopaminergic neurons express key markers like Nurr1 and release dopamine.
- Precursors remain viable after long-term storage and multiple freeze-thaw cycles.
NR4A nuclear orphan receptors: protective in vascular disease?
Pols TW, Bonta PI, de Vries CJ
This review discusses how NR4A nuclear receptors influence metabolism and vascular health in the context of cardiovascular disease. It does not provide information relevant to NR4A2-related neurological syndromes or potential treatments for children.
- The paper focuses on vascular disease, not neurological development or movement disorders.
- It reviews NR4A1, NR4A2, and NR4A3 roles in metabolism and blood vessel health.
- No clinical data, patient phenotypes, or therapeutic strategies for NR4A2 syndrome are presented.
- The content is unrelated to dopaminergic neuron function or Parkinson's disease mechanisms.
Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.
Kalinichev M, Robbins MJ, Hartfield EM, Maycox PR, Moore SH, Savage KM, Austin NE, Jones DN
This study compares two ways of giving PCP to rats and finds that the subcutaneous route causes stronger and longer-lasting behavioral changes and greater brain gene activity than the intraperitoneal route, due to higher drug levels in the blood and brain. The results help define a more reliable animal model for studying acute psychosis.
- Subcutaneous PCP causes stronger hyperactivity than intraperitoneal
- Subcutaneous route leads to higher brain and blood PCP levels
- More genes related to brain activity are turned on with subcutaneous dosing
- This method creates a more consistent model of acute psychosis
- Findings help improve animal models for studying psychosis
A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling.
Kitagawa H, Ray WJ, Glantschnig H, Nantermet PV, Yu Y, Leu CT, Harada S, Kato S, Freedman LP
This study maps how Wnt signaling proteins physically interact with Nurr1 to switch it from a repressor to an activator of gene expression. It identifies a specific feedback loop where the resulting genes help regulate the Wnt signal itself, providing a detailed molecular mechanism for Nurr1 regulation.
- Beta-catenin binds Nurr1 and removes corepressors to activate target genes.
- The study identifies KCNIP4 as a gene responsive to both Nurr1 and Wnt signaling.
- KCNIP4 creates a negative feedback loop that limits beta-catenin activity.
- This mechanism explains how Wnt signals regulate Nurr1 function in dopaminergic neurons.
Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition.
O'Kane M, Markham T, McEvoy AN, Fearon U, Veale DJ, FitzGerald O, Kirby B, Murphy EP
NURR1, a gene linked to neurological development and function, is abnormally increased in psoriasis skin and linked to disease severity. TNF-alpha blockers reduce NURR1 levels and restore its normal location in cells, suggesting a possible mechanism for how these drugs work.
- NURR1 is overexpressed in psoriasis skin
- Higher NURR1 levels match worse symptoms
- TNF-alpha inhibitors lower NURR1 levels
- NURR1 moves from nucleus to cytoplasm after treatment
- NURR1 may be a key player in inflammation
Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells.
Zhang T, Jia N, Fei E, Wang P, Liao Z, Ding L, Yan M, Nukina N, Zhou J, Wang G
This study shows that a specific cellular signaling pathway (ERK2) modifies the Nurr1 protein, which in turn increases the production of tyrosine hydroxylase, a key enzyme for dopamine synthesis. The findings are based entirely on cell culture experiments and do not involve human patients or animal models.
- ERK2 phosphorylates Nurr1 at specific sites near its activation domain.
- This modification enhances Nurr1's ability to drive tyrosine hydroxylase expression.
- The research uses only SH-SY5Y human neuroblastoma cell lines.
- No clinical data or patient outcomes are reported in this study.
Specification of a dopaminergic phenotype from adult human mesenchymal stem cells.
Trzaska KA, Kuzhikandathil EV, Rameshwar P
Adult human bone marrow stem cells convert into dopamine-producing neurons in a laboratory dish within 12 days. These induced cells express key dopamine markers and release dopamine, though they remain at an immature progenitor stage.
- Adult human bone marrow stem cells become dopamine neurons in 12 days.
- Induction uses sonic hedgehog and fibroblast growth factors.
- Approximately 67% of cells express tyrosine hydroxylase.
- Cells secrete dopamine but lack mature voltage-gated channels.
- Results demonstrate in vitro generation of dopaminergic progenitors.
Trophism of neural progenitor cells to embryonic stem cells: neural induction and transplantation in a mouse ischemic stroke model.
Fong SP, Tsang KS, Chan AB, Lu G, Poon WS, Li K, Baum LW, Ng HK
This study shows that neural progenitor cells can guide embryonic stem cells to become neural cells, improving brain function in mice with stroke. The process works without direct contact, relying on chemical signals, and produces cells that resemble neurons, astrocytes, and oligodendrocytes.
- Neural progenitor cells help stem cells become brain cells
- No unwanted cell types like muscle or gut cells formed
- Treated mice showed better brain function after stroke
- Most transplanted cells stayed near the injection site
- One tumor formed, but most cells were safe and functional
Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease.
Chen CM, Chen IC, Chang KH, Chen YC, Lyu RK, Liu YT, Hu FJ, Chao CY, Lee-Chen GJ, Wu YR
The NR4A2 IVS6 +18insG genetic variation may slightly lower the risk of Parkinson's disease in Taiwanese women, but not in men or overall. No clear link was found between this or the BDNF V66M variant and Parkinson's disease risk or age of onset in this study.
- NR4A2 IVS6 +18insG may reduce Parkinson’s risk in Taiwanese women
- No overall link between NR4A2 or BDNF variants and Parkinson’s in the group
- BDNF V66M did not affect disease onset age
- Findings were only significant in women after subgroup analysis
- No strong evidence for these variants influencing Parkinson’s in men
cDNA microarray analysis of cyclosporin A (CsA)-treated human peripheral blood mononuclear cells reveal modulation of genes associated with apoptosis, cell-cycle regulation and DNA repair.
Baião AM, Wowk PF, Sandrin-Garcia P, Junta CM, Fachin AL, Mello SS, Sakamoto-Hojo ET, Donadi EA, Passos GA
This study identifies NR4A2 as one of several genes whose expression changes in immune cells treated with the immunosuppressant cyclosporin A. The findings describe a molecular interaction between an unrelated drug and NR4A2 but do not provide information on the gene's natural function, disease mechanisms, or potential treatments for NR4A2-related syndromes.
- NR4A2 expression changes in immune cells treated with cyclosporin A.
- The study focuses on drug-induced gene modulation, not NR4A2 biology.
- No clinical data or treatment implications for NR4A2 syndromes are presented.
- Findings are limited to peripheral blood mononuclear cell experiments.
Cross-talk between the NR3B and NR4A families of orphan nuclear receptors.
Lammi J, Rajalin AM, Huppunen J, Aarnisalo P
This study demonstrates that NR4A2 (Nurr1) and related receptors mutually repress each other's activity through direct protein interactions. This mechanism modulates the transcriptional output of these nuclear receptors in specific cell types like osteoblasts.
- NR3B and NR4A receptor families mutually repress each other's transcriptional activity.
- Repression requires intact DNA-binding domains and dimerization interfaces.
- The mechanism does not involve competition for DNA binding sites.
- Activation functions of the receptors are not required for this cross-talk.
- This interaction modulates nuclear receptor activity in co-expressed cell types.
Merging mouse transcriptome analyses with Parkinson's disease linkage studies.
Gherbassi D, Bhatt L, Thuret S, Simon HH
This study uses mouse brain data to identify candidate genes for Parkinson's disease, including NR4A2. It does not provide new clinical information or treatment insights for children with NR4A2-related syndromes.
- The paper focuses on identifying genetic causes of adult-onset Parkinson's disease.
- It confirms NR4A2 is expressed in dopamine neurons relevant to Parkinson's pathology.
- No human clinical data, phenotypes, or treatment outcomes for NR4A2 variants are reported.
- The findings do not address the neurodevelopmental aspects of NR4A2 syndrome.
Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts.
Huang MS, Morony S, Lu J, Zhang Z, Bezouglaia O, Tseng W, Tetradis S, Demer LL, Tintut Y
Atherogenic phospholipids block bone-building signals from BMP-2 and parathyroid hormone in bone cells, which may reduce the effectiveness of bone-building treatments in people with high cholesterol or atherosclerosis.
- Atherogenic lipids inhibit bone formation signals
- They reduce response to BMP-2 and PTH treatments
- This may weaken bone-building therapies in high-risk patients
- The effect is linked to ERK pathway activation
- Suggests heart disease risk may impact bone treatment success
Mono-(2-ethylhexyl) phthalate (MEHP) induces nuclear receptor 4A subfamily in NCI-H295R cells: a possible mechanism of aromatase suppression by MEHP.
Noda M, Ohno S, Nakajin S
MEHP, a breakdown product of a common plasticizer, suppresses aromatase activity in human adrenal cells by rapidly increasing levels of the Nur77 protein, which in turn blocks the gene responsible for making aromatase. This effect is linked to activation of specific cellular signaling pathways.
- MEHP reduces aromatase, a key hormone-making enzyme
- MEHP boosts Nur77 protein levels quickly in human cells
- Nur77 directly suppresses aromatase gene activity
- This effect involves known cellular signaling pathways
- Findings suggest environmental chemicals may disrupt hormone balance
Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro.
Volpicelli F, Caiazzo M, Greco D, Consales C, Leone L, Perrone-Capano C, Colucci D'Amato L, di Porzio U
This study identifies Bdnf as a direct target gene of the Nurr1 transcription factor in rat neurons, showing that Nurr1 regulates Bdnf expression to support dopaminergic neuron development. The findings confirm a molecular mechanism where Nurr1 directly controls Bdnf levels through specific signaling pathways.
- Nurr1 directly regulates Bdnf gene expression in rat midbrain neurons.
- Decreased Nurr1 leads to reduced BDNF protein and mRNA levels.
- BDNF is essential for the maturation of dopaminergic neurons.
- The study uses rat cell cultures, not human patients or clinical data.
Adult mice with reduced Nurr1 expression: an animal model for schizophrenia.
Rojas P, Joodmardi E, Hong Y, Perlmann T, Ogren SO
This study uses mice with reduced Nurr1 levels to model schizophrenia, finding behavioral changes and altered dopamine activity that do not directly address the movement disorders associated with NR4A2 syndrome in children. The findings focus on psychiatric symptoms and general dopaminergic mechanisms rather than the specific clinical phenotype or treatment options for NR4A2-related conditions.
- Mice with reduced Nurr1 show hyperactivity and memory deficits resembling schizophrenia.
- The study models psychiatric symptoms, not the motor issues seen in NR4A2 syndrome.
- Dopamine turnover changes differ between male and female mice brain regions.
- No human data or direct treatment implications for NR4A2 patients are provided.
NR4A nuclear receptors in atherosclerosis and vein-graft disease.
Bonta PI, Pols TW, de Vries CJ
NR4A nuclear receptors, including Nurr1, play roles in vascular diseases like atherosclerosis and vein graft failure by regulating cell behavior in blood vessels. These receptors influence inflammation, cell survival, and tissue repair in the context of vascular injury.
- NR4A receptors regulate blood vessel health and disease
- Nurr1 affects inflammation and cell survival in vessels
- These receptors are involved in vein graft failure and atherosclerosis
- Potential target for treating vascular damage
Discovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies.
Poppe L, Harvey TS, Mohr C, Zondlo J, Tegley CM, Nuanmanee O, Cheetham J
Researchers use nuclear magnetic resonance techniques to identify and optimize small molecules that bind to the Nurr1 protein. This work establishes a method for finding chemical compounds that interact with Nurr1, but it does not test these compounds in living organisms or humans.
- The study identifies weak-binding ligands for the Nurr1 protein using advanced NMR screening methods.
- It maps the specific binding site on the Nurr1 protein through residue-specific labeling.
- No animal models, human trials, or therapeutic efficacy data are included in this report.
[Human bone marrow mesenchymal stem cells differentiated into dopaminergenic neurons in vitro].
Chai LH, Wu SX, Yan WH, Ma YF
This study demonstrates that human bone marrow stem cells can be converted into dopamine-producing neurons in a laboratory dish using specific chemical signals. The resulting cells express key genetic markers and release dopamine, suggesting they could potentially serve as a source for cell replacement therapies in conditions like Parkinson's disease.
- Human bone marrow stem cells differentiate into dopamine neurons in vitro.
- Cells express Nurr1, TH, and other dopaminergic neuron markers.
- Differentiated cells release measurable amounts of dopamine.
- This is preclinical research using cell cultures, not human trials.
- No connection to NR4A2 syndrome or genetic treatment strategies.
A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue.
Ralph JA, Zocco D, Bresnihan B, Fitzgerald O, McEvoy AN, Murphy EP
This study finds that a specific receptor for stress-related hormones (CRH-R1alpha) is produced by blood vessel cells in inflamed joints and drives inflammation, partly by activating a gene called NR4A2. The hormone histamine boosts this receptor, and the pathway involves key signaling molecules linked to immune responses and tissue damage.
- CRH-R1alpha is made in joint blood vessels during chronic inflammation
- Histamine increases CRH-R1alpha via its own receptor
- CRH-R1alpha activates NR4A2 and inflammation-related genes
- This pathway promotes nitric oxide production and tissue damage
- Targeting this pathway may reduce joint inflammation
Adrenal transcription regulatory genes modulated by angiotensin II and their role in steroidogenesis.
Romero DG, Rilli S, Plonczynski MW, Yanes LL, Zhou MY, Gomez-Sanchez EP, Gomez-Sanchez CE
This study identifies NR4A2 as a gene that increases the expression of enzymes responsible for producing steroid hormones in adrenal cells. It specifically highlights that NR4A2 preferentially upregulates the pathway for mineralocorticoids, which regulate salt and water balance, over glucocorticoids.
- NR4A2 increases enzyme expression for both glucocorticoid and mineralocorticoid pathways in adrenal cells.
- NR4A2 shows greater selectivity for upregulating the mineralocorticoid biosynthetic pathway.
- The study uses human adrenal cell lines to map transcriptional regulation by angiotensin II.
- Abnormal regulation of these pathways may contribute to adrenal steroidogenesis pathologies.
Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURR1 in cartilage.
Mix KS, Attur MG, Al-Mussawir H, Abramson SB, Brinckerhoff CE, Murphy EP
NURR1, a protein linked to NR4A2, reduces the production of enzymes that break down cartilage in joints during inflammation. It works by blocking specific genes (MMP-1, MMP-3, MMP-9) without affecting others, suggesting a protective role in joint health.
- NURR1 reduces harmful cartilage-degrading enzymes
- It targets MMP genes involved in joint damage
- NURR1 opposes inflammatory signals in cartilage
- May help protect joints in inflammatory conditions
Manipulation of proliferation and differentiation of human bone marrow-derived neural stem cells in vitro and in vivo.
Zeng Z, Yuan X, Liu G, Zeng X, Zeng X, Ng H, Chen H, Jiang T, Akasaki Y, Kessey K, Black KL, Yu JS
Overexpressing Nurr1 in human bone marrow-derived neural stem cells promotes their migration and differentiation into neural lineages when transplanted into chicken embryos. While this demonstrates that Nurr1 influences neural development, the study uses non-human animal models and does not test treatments or outcomes in humans with NR4A2-related syndromes.
- Nurr1 overexpression drives migration and differentiation of human neural stem cells in chicken embryos.
- Other factors like Gli-1 and Shh primarily increased cell proliferation rather than differentiation.
- The study uses preclinical animal models, not human patients or clinical trials.
- No evidence is provided regarding treatment efficacy for NR4A2-related neurodevelopmental disorders.
Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra.
Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, Dexter DT, Pearce RK, Graeber MB
This study reports reduced expression of the NR4A2 gene in the substantia nigra of adults with sporadic Parkinson's disease, alongside other dopaminergic pathway changes. It does not provide information on NR4A2-related developmental syndromes or potential treatments for children.
- NR4A2 expression is reduced in the substantia nigra of sporadic Parkinson's patients.
- The study focuses on adult neurodegeneration, not pediatric developmental disorders.
- No clinical trials or therapeutic interventions for NR4A2 syndromes are described.
- Findings relate to disease mechanisms in adults, not genetic causes in children.
Induction of tyrosine hydroxylase expression by the transcription factor Pitx3.
Messmer K, Remington MP, Skidmore F, Fishman PS
This study shows that combining the transcription factors Pitx3 and Nurr1 does not boost tyrosine hydroxylase expression more than using either factor alone in stem cells. The findings suggest that additional regulatory elements are needed for robust dopaminergic differentiation, implying that simple co-expression of these two factors is insufficient for therapeutic strategies.
- Pitx3 and Nurr1 do not synergize to increase tyrosine hydroxylase expression in stem cells.
- Combined expression yields no greater effect than individual factor expression.
- Other regulatory elements likely control tyrosine hydroxylase levels beyond these two factors.
- Robust differentiation may require sequential or combinatorial treatments with different factors.
Nuclear receptor 4A2 and C/EBPbeta regulate the parathyroid hormone-mediated transcriptional regulation of the 25-hydroxyvitamin D3-1alpha-hydroxylase.
Zierold C, Nehring JA, DeLuca HF
This study identifies a mechanism in kidney cells where NR4A2 helps regulate vitamin D activation, but it does not address the neurological or developmental aspects of NR4A2-related syndrome. The findings are limited to basic molecular biology in porcine kidney tissue and offer no direct insight into treatment or symptom management for your child. This research is unrelated to the dopaminergic pathways typically associated with NR4A2 function in the brain.
- NR4A2 regulates vitamin D activation enzymes in kidney cells, not brain neurons.
- The study uses porcine kidney cell lines, which are not human models.
- No connection is made to neurodevelopmental phenotypes or motor symptoms.
- Findings do not inform current clinical management or therapeutic strategies for NR4A2 syndrome.
Profile of immediate early gene expression in the lumbar spinal cord of low-thoracic paraplegic mice.
Landry ES, Rouillard C, Levesque D, Guertin PA
This study examines immediate early gene expression in the spinal cords of mice with paraplegia to understand neuronal plasticity after injury. It finds that c-fos and nor-1 levels change significantly, while nurr1 (NR4A2) transcripts are not detected before or after the spinal transection. The research focuses on general spinal cord repair mechanisms rather than NR4A2-specific functions relevant to neurodevelopmental syndromes.
- The study uses a mouse model of low-thoracic spinal cord injury.
- Nurr1 (NR4A2) transcripts are undetectable in the lumbar spinal cord.
- C-fos and nor-1 show distinct expression changes post-injury.
- Findings relate to sensorimotor integration and locomotor control plasticity.
- No human data or direct NR4A2 syndrome implications are presented.
In vitro differentiation of cord blood unrestricted somatic stem cells expressing dopamine-associated genes into neuron-like cells.
Fallahi-Sichani M, Soleimani M, Najafi SM, Kiani J, Arefian E, Atashi A
This study shows that stem cells from human umbilical cord blood can be coaxed in a lab dish to express genes associated with dopamine-producing neurons. The researchers identify specific genetic markers like Nurr1 in these modified cells, suggesting they might serve as a source for cell therapies for Parkinson's disease.
- Cord blood stem cells develop neuron-like features when grown without serum.
- These cells express key genes required for dopaminergic neuron development and survival.
- The findings propose cord blood stem cells as potential candidates for Parkinson's cell therapy.